ASND vs. ONC: Ascendis Pharma vs. BeOne Medicines Stock Comparison
How do Ascendis Pharma (ASND) and BeOne Medicines (ONC) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Ascendis Pharma (ASND) and BeOne Medicines (ONC) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
Ascendis Pharma (ASND) trades as ordinary local shares, while BeOne Medicines (ONC) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | ASND | ONC |
|---|---|---|
| Name | Ascendis Pharma A/S | BeOne Medicines Ltd. American Depositary Shares |
| Country/Region | Denmark | Switzerland |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 16.90 billion USD | 46.49 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | January 28, 2015 | February 3, 2016 |
| Security Type | Common Stock | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ASND | ONC |
|---|---|---|
| Total Return (1Y) | 29.46% | 30.59% |
| Total Return (3Y, Annualized) | 40.62% | 30.15% |
| Total Return (5Y, Annualized) | 10.03% | 2.48% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ASND | ONC |
|---|---|---|
| Volatility (1Y, Annualized) | 38.62% | 35.90% |
| Beta (5Y) | 0.38 | 0.59 |
| Max Drawdown (5Y) | -55.93% | -68.89% |
| Avg. Volume (3M) | 698.39K | 405.29K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ASND | ONC |
|---|---|---|
| Sharpe Ratio (1Y) | 0.65 | 0.73 |
| Sortino Ratio (1Y) | 0.99 | 1.15 |
Profitability
ROE (TTM)
Both companies show strong equity returns, but Ascendis Pharma (ASND) at 118.78% is the standout with ROE above its industry range; BeOne Medicines (ONC) at 18.40% also sits in the top quartile.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
118.78%
- ASND
- 118.78%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.40%
- Max
- 109.18%
- ONC
- 18.40%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Ascendis Pharma (ASND) at 70.85% keeps the most of each sales dollar — above its industry’s net margin range — and BeOne Medicines (ONC) at 13.86% also retains a top-quartile share.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
70.85%
- ASND
- 70.85%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.86%
- Max
- 18.05%
- ONC
- 13.86%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Ascendis Pharma (ASND) at 64.98% and BeOne Medicines (ONC) at 22.15% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
64.98%
- Max
- 83.12%
- ASND
- 64.98%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.15%
- Max
- 83.12%
- ONC
- 22.15%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ASND | ONC |
|---|---|---|
| ROE (TTM) | 118.78% | 18.40% |
| ROA (TTM) | 9.58% | 8.42% |
| Net Margin (TTM) | 70.85% | 13.86% |
| Operating Margin (TTM) | 64.98% | 22.15% |
| Gross Margin (TTM) | 91.30% | 89.39% |
Growth
Revenue Growth
Ascendis Pharma (ASND) at 98.03% sits in the top revenue growth quartile, while BeOne Medicines (ONC) at 40.23% is closer to the peer norm — faster top-line expansion for ASND.
EPS Growth
Neither Ascendis Pharma (ASND) nor BeOne Medicines (ONC) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | ASND | ONC |
|---|---|---|
| Revenue Growth (YoY) | 98.03% | 40.23% |
| Revenue Growth (3Y CAGR) | 141.43% | 55.69% |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Both Ascendis Pharma (ASND) at 2.99 and BeOne Medicines (ONC) at 3.55 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.99
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ASND
- 2.99
- Q1
- 2.47
- Min
- 0.10
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.55
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ONC
- 3.55
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both Ascendis Pharma (ASND) at 0.31 and BeOne Medicines (ONC) at 0.35 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.31
- Max
- 1.42
- Q3
- 0.65
- ASND
- 0.31
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.35
- Max
- 1.42
- Q3
- 0.65
- ONC
- 0.35
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ASND | ONC |
|---|---|---|
| Current Ratio (MRQ) | 2.99 | 3.55 |
| Debt / Equity (MRQ) | 0.31 | 0.35 |
| Net Debt / EBITDA | -1.37 | -2.80 |
Dividends
Dividend Yield (TTM)
Neither Ascendis Pharma (ASND) nor BeOne Medicines (ONC) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ASND
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Ascendis Pharma (ASND) nor BeOne Medicines (ONC) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ASND
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ASND | ONC |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Ascendis Pharma (ASND) at 19.68 is near its industry’s usual P/E ratio, while BeOne Medicines (ONC) at 52.17 sits in the richer quartile — ONC needs stronger growth or earnings quality to justify the premium.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.68
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- ASND
- 19.68
- Q1
- 13.30
- Min
- 0.07
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.17
- Max
- 85.34
- ONC
- 52.17
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Ascendis Pharma (ASND) at 16.14 and BeOne Medicines (ONC) at 7.04 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.14
- Max
- 58.18
- Q3
- 25.77
- ASND
- 16.14
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.04
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ONC
- 7.04
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Both Ascendis Pharma (ASND) at 10.45 and BeOne Medicines (ONC) at 7.98 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.45
- Max
- 13.53
- ASND
- 10.45
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.98
- Max
- 13.53
- ONC
- 7.98
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ASND | ONC |
|---|---|---|
| P/E Ratio (TTM) | 19.68 | 52.17 |
| P/S Ratio (TTM) | 16.14 | 7.04 |
| P/B Ratio (MRQ) | 10.45 | 7.98 |
| Free Cash Flow Yield (TTM) | 0.08% | 2.21% |